Literature DB >> 24443099

Effect of COMT Val108/158Met genotype on risk for polydipsia in chronic patients with schizophrenia.

Kenji Yamada1, Takahiro Shinkai, Hsin-I Chen, Kensuke Utsunomiya, Jun Nakamura.   

Abstract

Polydipsia is a serious condition often seen among patients with schizophrenia (SCZ). The cause of polydipsia is unknown; hence, it is hard to treat or manage. Animal studies showed that the drinking behavior is regulated by central dopaminergic neurotransmission at the hypothalamus. Meanwhile, the existence of a genetic predisposition to polydipsia in patients with SCZ has been suggested. The purpose of this study was to assess whether a functional polymorphism, Val(108/158)Met in the gene for catechol-O-methyltransferase (COMT), is associated with susceptibility to polydipsia using a Japanese sample of SCZ. Our sample includes 330 chronic patients with SCZ (83 polydipsic patients and 247 non-polydipsic controls). The common COMT Val(108/158)Met polymorphism was genotyped, and the differences in genotype distribution and allele frequency between cases and controls were evaluated using the χ(2) test. A significant association between the COMT Val(108/158)Met polymorphism and polydipsia was found (genotype distribution: χ(2) = 13.0, df = 2, p = 0.001; allele frequency: χ(2) = 7.50, df = 1, p = 0.006). The high-COMT activity group (Val/Val) was more frequent among patients with polydipsia compared with the low-COMT activity group (Val/Met + Met/Met) [odds ratio (OR) = 2.46]. The association survived after controlling for other possible confounding factors, including gender, age, age of onset, current antipsychotic dose, and smoking status. Our results suggest that the COMT Val(108/158)Met genotype may confer susceptibility to polydipsia in SCZ. To our knowledge, this is the first association study between the COMT gene and polydipsia in SCZ. Further studies with larger sample sizes are warranted to confirm present findings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24443099     DOI: 10.1007/s12017-014-8287-9

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  38 in total

1.  ADH secretion in schizophrenic patients on antipsychotic drugs.

Authors:  M Sarai; H Matsunaga
Journal:  Biol Psychiatry       Date:  1989-10       Impact factor: 13.382

2.  Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia.

Authors:  M B Goldman; D J Luchins; G L Robertson
Journal:  N Engl J Med       Date:  1988-02-18       Impact factor: 91.245

3.  Clozapine for polydipsia and hyponatremia in chronic schizophrenics.

Authors:  D C Henderson; D C Goff
Journal:  Biol Psychiatry       Date:  1994-12-01       Impact factor: 13.382

4.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia.

Authors:  M F Egan; T E Goldberg; B S Kolachana; J H Callicott; C M Mazzanti; R E Straub; D Goldman; D R Weinberger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

5.  Increased urine volume in chronic schizophrenic patients.

Authors:  W B Lawson; C N Karson; L B Bigelow
Journal:  Psychiatry Res       Date:  1985-04       Impact factor: 3.222

6.  Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism.

Authors:  Jennifer H Barnett; Linda Scoriels; Marcus R Munafò
Journal:  Biol Psychiatry       Date:  2008-03-14       Impact factor: 13.382

7.  Self-induced water intoxication in schizophrenic patients.

Authors:  W O Smith; M L Clark
Journal:  Am J Psychiatry       Date:  1980-09       Impact factor: 18.112

8.  Manners of arginine vasopressin secretion in schizophrenic patients--with reference to the mechanism of water intoxication.

Authors:  T Kishimoto; M Hirai; H Ohsawa; M Terada; I Matsuoka; G Ikawa
Journal:  Jpn J Psychiatry Neurol       Date:  1989-06

Review 9.  Genomic approaches to schizophrenia.

Authors:  Michael J Owen
Journal:  Clin Ther       Date:  2005       Impact factor: 3.393

10.  Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications.

Authors:  H Y Tan; A G Chen; Q Chen; L B Browne; B Verchinski; B Kolachana; F Zhang; J Apud; J H Callicott; V S Mattay; D R Weinberger
Journal:  Mol Psychiatry       Date:  2011-07-26       Impact factor: 15.992

View more
  2 in total

1.  Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach.

Authors:  Ying Hu; Zhonghai Fang; Yichen Yang; Dekai Rohlsen-Neal; Feng Cheng; Ju Wang
Journal:  Sci Rep       Date:  2018-02-13       Impact factor: 4.379

Review 2.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.